Latest news

We are growing and have moved!

Bioservo Technologies announces the start of the clinical study for Carbonhand® within the framework of the Horizon 2020 iHand project

World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies


12 Sep, 2018

Bioservo’ s Board of Directors proposes a stock option program

Today Bioservo’ s Board of Directors has decided to propose an additional shareholder meeting in order to agree on a long-term share option program directed towards employees. The main reason is to encourage broad shareholding among Bioservo’ s employees, as well as attracting and retaining competent employees, strengthening the link to Bioservo’ s shareholders' interests.

The maximum number of shares that can be issued within the long-term stock option program is limited and should not exceed the equivalent of 4.5 percent of the total number of outstanding shares. The Board's complete proposal regarding Bioservo's long-term stock option program will be published in conjunction with a notice announcing an additional shareholder meeting scheduled for October 2, 2018

About Bioservo Technologies AB 

Bioservo Technologies (publ) is a technology and development company that combines medical science with modern robotics. The company has a leading global position within soft exoskeleton technology, wearable non-invasive products, for people in need of extra power to support the body's endurance and performance, or for people with reduced muscular strength.

After many years of research and development, Bioservo Technologies now focus on the commercialization of its products and patented technologies. The developed gloves are well suited for both rehabilitation within health and medical care and preventively for professionals in the industry. The company has signed strategic cooperation agreements with several multinational companies within e.g. the automobile, aircraft as well as the construction and infrastructure industry.

Bioservo Technologies was founded in 2006 through a collaboration between researchers at the Royal Institute of Technology and doctors at Karolinska University Hospital in Stockholm. Bioservo Technologies is a Swedish public company with headquarters and operations in Kista, north of Stockholm.

FNCA Sweden AB is the company's Certified Adviser on Nasdaq First North.

For more information, please visit 

Bioservo Technologies AB contact 

Petter Bäckgren


Phone: +46 (0)70 555 69 97                                                       

Maria Myräng


Phone: +46 (0) 70 622 54 93